Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer

Cancer statistics, 2023

(2023) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer

(2023) Abhenil Mittal et al.   Cancers

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

(2022) Francois-Clement Bidard et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

(2022) William J. Gradishar et al.   Journal of the National Comprehensive Cancer Network

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

(2021) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Endocrine-Resistant Breast Cancer: Mechanisms and Treatment

(2020) Andreas D. Hartkopf et al.   Breast Care

Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women

(2020) Maureen G. Conlan et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment

(2018) Hitisha K. Patel et al.   PHARMACOLOGY & THERAPEUTICS

RAD1901

(2015) Fiona Garner et al.   ANTI-CANCER DRUGS

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

(2015) Rinath Jeselsohn et al.   Nature Reviews Clinical Oncology